科兴制药：公司简评报告：海外业务快速增长，盈利能力持续提升

Investment Rating - The investment rating for the company is "Accumulate" [2] Core Views - The company is experiencing rapid growth in overseas business, with profitability continuing to improve [2] - Domestic business showed short-term fluctuations but is expected to remain stable in the long term [4] - The company's profitability is improving, with potential for further profit margin enhancement [4] - The overseas business is entering a phase of accelerated growth, with significant revenue increases expected [7] Summary by Sections Financial Performance - For the first three quarters of 2024, the company achieved revenue of 1.038 billion yuan, a year-on-year increase of 7.15%, with a net profit attributable to shareholders of 17.18 million yuan [6] - The revenue from overseas operations reached 149 million yuan, up 47.16% year-on-year, with Q3 2024 overseas revenue growing by 93.29% [7] Revenue and Profit Forecast - Revenue projections for 2024 to 2026 are 1.349 billion yuan, 1.721 billion yuan, and 2.087 billion yuan, with year-on-year growth rates of 7.1%, 27.6%, and 21.3% respectively [5] - Net profit attributable to shareholders is forecasted to be 30 million yuan, 97 million yuan, and 197 million yuan for the same period, with growth rates of 222.3% and 104.0% [5] Market Position and Strategy - The company has strengthened its overseas market presence, establishing a subsidiary in Germany to enhance sales of its products in the EU and UK [7] - Key products have received regulatory approvals in various international markets, indicating a robust pipeline for future growth [7]